Literature DB >> 27881554

O PIONEERs! The Beginning of the End of Full-Dose Triple Therapy with Warfarin?

Deepak L Bhatt1.   

Abstract

Entities:  

Keywords:  Editorials

Mesh：

Substances：

Year:  2016        PMID： 27881554     DOI： 10.1161/CIRCULATIONAHA.116.025923

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

Review 1.  [Anticoagulation-direct oral anticoagulants].

Authors:  B Kemkes-Matthes
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

Review 2.  Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?

Authors:  Emanuel Raschi; Matteo Bianchin; Cecilia Fantoni; Walter Ageno; Fabrizio De Ponti; Roberto De Ponti
Journal:  Intern Emerg Med       Date:  2017-08-07       Impact factor: 3.397

3.  Changing patterns of upper gastrointestinal bleeding over 23 years in Turkey.

Authors:  Nilay Danış; Fatih Tekin; Ulus Salih Akarca; Nalan Gülsen Ünal; Elvan Işık Erdoğan; Kıvanç Akat; Ümit Demirkoparan; Zeki Karasu; İlker Turan; Nevin Oruç; Ahmet Aydın; Galip Ersöz; Rukiye Vardar; Ömer Özütemiz; Fulya Günşar
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

4.  Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.

Authors:  Taku Inohara; Ying Xian; Li Liang; Roland A Matsouaka; Jeffrey L Saver; Eric E Smith; Lee H Schwamm; Mathew J Reeves; Adrian F Hernandez; Deepak L Bhatt; Eric D Peterson; Gregg C Fonarow
Journal:  JAMA       Date:  2018-02-06       Impact factor: 56.272

Review 5.  Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?

Authors:  Benjamin E Peterson; Deepak L Bhatt
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

6.  Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Harsh B Golwala; Christopher P Cannon; Ph Gabriel Steg; Gheorghe Doros; Arman Qamar; Stephen G Ellis; Jonas Oldgren; Jurrien M Ten Berg; Takeshi Kimura; Stefan H Hohnloser; Gregory Y H Lip; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2018-05-14       Impact factor: 35.855

Review 7.  Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials.

Authors:  Vincent Roule; Pierre Ardouin; Clément Briet; Adrien Lemaitre; Mathieu Bignon; Rémi Sabatier; Laure Champ-Rigot; Paul Milliez; Katrien Blanchart; Farzin Beygui
Journal:  Clin Cardiol       Date:  2019-07-09       Impact factor: 2.882

8.  Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study.

Authors:  Chiao-Chin Lee; Chiao-Hsiang Chang; Yuan Hung; Chin-Sheng Lin; Shih-Ping Yang; Shu-Meng Cheng; Fan-Han Yu; Wei-Shiang Lin; Wen-Yu Lin
Journal:  Thromb J       Date:  2021-12-14

9.  2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.

Authors:  Chern-En Chiang; Ken Okumura; Shu Zhang; Tze-Fan Chao; Chung-Wah Siu; Toon Wei Lim; Anil Saxena; Yoshihide Takahashi; Wee Siong Teo
Journal:  J Arrhythm       Date:  2017-06-27

Review 10.  The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly.

Authors:  Leonardo Bencivenga; Klara Komici; Graziamaria Corbi; Antonio Cittadini; Nicola Ferrara; Giuseppe Rengo
Journal:  Front Physiol       Date:  2018-07-09       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.